Hua Shao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hua Shao has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Linlin Hu
Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China; Office of Medication Clinical Institution, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
7 shared publicationsJie He
Department of Pharmacy, Zhongda Hospital,Southeast University, Nanjing, 210009, China
4 shared publicationsLingjun Zhong
Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
3 shared publicationsDongxue Liu
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
2 shared publicationsFeng Yu
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
2 shared publicationsGaoqiu Dong
Department of Pharmacy, Zhongda Hospital,Southeast University, Nanjing, 210009, China
2 shared publications
Latest Publications
- Open Access
- 9 May 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Design and evaluation of a bifunctional fusion polypeptide for targeted delivery of tigecycline against drug-resistant Klebsiella pneumoniae
The overuse of antibiotics and the continuous evolution of drug-resistant bacteria present substantial obstacles to the clinical treatment of Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. This study reports the rational design of a bifunctional fusion polypeptide, S-thanatin (Ts)-functionalized elastin-like carrier (Ts-ELP), which integrates the antimicrobial peptide (AMP) Ts with a human-derived elastin‑like polypeptides (ELPs). This designer polypeptide serves as a smart carrier, capable of efficiently encapsulating the broad-spectrum antibiotic tigecycline (Tig) via reversible temperature-responsive phase transition hydrophobic interaction, resulting in a self-assembled, targeted nano-antibiotic, Tig@Ts-ELP (Tig@TsE). Comprehensive in vitro and in vivo evaluations demonstrate that Tig@TsE exhibits multiple advantageous features, including rapid and simple preparation, specific lipopolysaccharide (LPS)-targeting capability, excellent in vivo targeted delivery efficiency, and dual-responsive drug release triggered by the acidic pH and elevated matrix metalloproteinase-9 (MMP-9) levels in the CRKP-infected microenvironment, coupled with favorable biocompatibility. Moreover, the Ts peptide and Tig exhibit marked synergistic antibacterial effects against CRKP. This innovative nano-antibiotic delivery system is designed to increase local drug concentration at the infection site, boost bactericidal activity, and reduce systemic toxicity, thereby presenting a promising therapeutic strategy for the treatment of drug-resistant bacterial pneumonia.
- 9 May 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessDesign and evaluation of a bifunctional fusion polypeptide for targeted delivery of tigecycline against drug-resistant Klebsiella pneumoniae
The overuse of antibiotics and the continuous evolution of drug-resistant bacteria present substantial obstacles to the clinical treatment of Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. This study reports the rational design of a bifunctional fusion polypeptide, S-thanatin (Ts)-functionalized elastin-like carrier (Ts-ELP), which integrates the antimicrobial peptide (AMP) Ts with a human-derived elastin‑like polypeptides (ELPs). This designer polypeptide serves as a smart carrier, capable of efficiently encapsulating the broad-spectrum antibiotic tigecycline (Tig) via reversible temperature-responsive phase transition hydrophobic interaction, resulting in a self-assembled, targeted nano-antibiotic, Tig@Ts-ELP (Tig@TsE). Comprehensive in vitro and in vivo evaluations demonstrate that Tig@TsE exhibits multiple advantageous features, including rapid and simple preparation, specific lipopolysaccharide (LPS)-targeting capability, excellent in vivo targeted delivery efficiency, and dual-responsive drug release triggered by the acidic pH and elevated matrix metalloproteinase-9 (MMP-9) levels in the CRKP-infected microenvironment, coupled with favorable biocompatibility. Moreover, the Ts peptide and Tig exhibit marked synergistic antibacterial effects against CRKP. This innovative nano-antibiotic delivery system is designed to increase local drug concentration at the infection site, boost bactericidal activity, and reduce systemic toxicity, thereby presenting a promising therapeutic strategy for the treatment of drug-resistant bacterial pneumonia.
- 27 April 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (8) , 107822
Risk factors and serum concentration thresholds associated with tigecycline-induced hepatotoxicity in critically ill patients
- 27 April 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (8) , 107822
Risk factors and serum concentration thresholds associated with tigecycline-induced hepatotoxicity in critically ill patients
- 25 September 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107632
Machine learning in antimicrobial therapy for critically ill patients: optimizing early empirical regimens, individualized dosing, and de-escalation strategies
- 25 September 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107632
Machine learning in antimicrobial therapy for critically ill patients: optimizing early empirical regimens, individualized dosing, and de-escalation strategies
- Open Access
- 18 August 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-14
Global, regional, and national epidemiology of type 1 diabetes in children from 1990 to 2021: trend and health inequality analyses based on the Global Burden of Disease Study 2021
Type 1 diabetes (T1D) is a significant health challenge for children. Assessing the epidemiological patterns and health inequalities associated with T1D at the global, regional, and national levels, along with future projections, is essential for informing equitable public health policies. Based on the Global Burden of Disease (GBD) 2021 database, this study examined trends in the incidence, prevalence, disability-adjusted life years (DALYs), and mortality of T1D in children aged 0–14 years. Attribution decomposition analysis was used to explore the main drivers of the changes in the T1D burden, including the effects of population growth, epidemiological changes, and fertility rates. Regression models and concentration curves were employed to evaluate health inequality among countries and regions with different sociodemographic index (SDI) levels, and predictive models were used to estimate future trends of T1D over the next 30 years. From 1990 to 2021, the global incidence and prevalence of T1D increased significantly, by 32.04% and 41.47%, respectively, whereas the global DALY and mortality rates decreased by 18.33% and 24.83%, respectively. Attribution decomposition analysis revealed that population growth and epidemiological improvements were the main drivers of the changes in the T1D burden. DALYs and mortality decreased significantly in high-SDI countries, whereas health inequality remained severe in low-SDI countries. The predictive models indicate that the incidence and prevalence of T1D among children worldwide will continue to rise in the coming decades, particularly among males. By 2050, DALYs and mortality are expected to decline further. Although the global T1D burden has increased, advances in medical technology, especially in high-SDI countries, have alleviated its health impacts. To reduce global health inequality, low-SDI countries must strengthen international cooperation by improving T1D prevention and control through resource sharing and the introduction of medical technologies.
- 18 August 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-14
Open AccessGlobal, regional, and national epidemiology of type 1 diabetes in children from 1990 to 2021: trend and health inequality analyses based on the Global Burden of Disease Study 2021
Type 1 diabetes (T1D) is a significant health challenge for children. Assessing the epidemiological patterns and health inequalities associated with T1D at the global, regional, and national levels, along with future projections, is essential for informing equitable public health policies. Based on the Global Burden of Disease (GBD) 2021 database, this study examined trends in the incidence, prevalence, disability-adjusted life years (DALYs), and mortality of T1D in children aged 0–14 years. Attribution decomposition analysis was used to explore the main drivers of the changes in the T1D burden, including the effects of population growth, epidemiological changes, and fertility rates. Regression models and concentration curves were employed to evaluate health inequality among countries and regions with different sociodemographic index (SDI) levels, and predictive models were used to estimate future trends of T1D over the next 30 years. From 1990 to 2021, the global incidence and prevalence of T1D increased significantly, by 32.04% and 41.47%, respectively, whereas the global DALY and mortality rates decreased by 18.33% and 24.83%, respectively. Attribution decomposition analysis revealed that population growth and epidemiological improvements were the main drivers of the changes in the T1D burden. DALYs and mortality decreased significantly in high-SDI countries, whereas health inequality remained severe in low-SDI countries. The predictive models indicate that the incidence and prevalence of T1D among children worldwide will continue to rise in the coming decades, particularly among males. By 2050, DALYs and mortality are expected to decline further. Although the global T1D burden has increased, advances in medical technology, especially in high-SDI countries, have alleviated its health impacts. To reduce global health inequality, low-SDI countries must strengthen international cooperation by improving T1D prevention and control through resource sharing and the introduction of medical technologies.
- 1 April 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 380, 734-741
The effects of six antidepressants on electrolytes, hepatic and renal functions, and glycolipid metabolism in patients with major depressive disorder
- 1 April 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 380, 734-741
The effects of six antidepressants on electrolytes, hepatic and renal functions, and glycolipid metabolism in patients with major depressive disorder
- 7 November 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 200-208
Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients
Hypofibrinogenaemia is a serious adverse reaction associated with tigecycline (TGC) therapy and may lead to the discontinuation of the treatment. This study aimed to explore the relevant factors of TGC-induced hypofibrinogenaemia and determine the thresholds of serum concentration as a predictive indicator of TGC-induced hypofibrinogenaemia. A retrospective single-centre study was conducted on patients with severe infection who were treated with TGC. Clinical data and serum concentration parameters were extracted from the electronic medical records of these patients. Patients were divided into the hypofibrinogenaemia group (< 2.0 g/L) and the normal fibrinogen group (≥ 2.0 g/L) in order to evaluate risk factors associated with TGC-induced hypofibrinogenaemia. Logistic regression analysis and receiver operating characteristic curves were utilized to identify the risk factors associated with TGC-induced hypofibrinogenaemia and to establish plasma concentration thresholds as predictive indicators. A total of 114 patients were enrolled in this study, with 59.6% experiencing hypofibrinogenaemia. The multivariate regression analysis indicated that baseline fibrinogen level, trough concentration (Cmin), peak concentration (Cmax), the concentration at 6 h after the dosing (C6h) and the area under the concentration–time curve over a 24-h period (AUC0–24) were significantly associated with hypofibrinogenaemia (P < 0.05). Furthermore, it was found that AUC0–24 is the optimal predictor of TGC-induced hypofibrinogenaemia. The optimal cut-off for the AUC0–24 of TGC in ICU patients was determined to be 17.03 mg h/L. TGC exposure is highly predictive of TGC-induced hypofibrinogenaemia. We recommend closely monitoring plasma concentrations of TGC in patients to ensure patient efficacy and safety.
- 7 November 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 200-208
Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients
Hypofibrinogenaemia is a serious adverse reaction associated with tigecycline (TGC) therapy and may lead to the discontinuation of the treatment. This study aimed to explore the relevant factors of TGC-induced hypofibrinogenaemia and determine the thresholds of serum concentration as a predictive indicator of TGC-induced hypofibrinogenaemia. A retrospective single-centre study was conducted on patients with severe infection who were treated with TGC. Clinical data and serum concentration parameters were extracted from the electronic medical records of these patients. Patients were divided into the hypofibrinogenaemia group (< 2.0 g/L) and the normal fibrinogen group (≥ 2.0 g/L) in order to evaluate risk factors associated with TGC-induced hypofibrinogenaemia. Logistic regression analysis and receiver operating characteristic curves were utilized to identify the risk factors associated with TGC-induced hypofibrinogenaemia and to establish plasma concentration thresholds as predictive indicators. A total of 114 patients were enrolled in this study, with 59.6% experiencing hypofibrinogenaemia. The multivariate regression analysis indicated that baseline fibrinogen level, trough concentration (Cmin), peak concentration (Cmax), the concentration at 6 h after the dosing (C6h) and the area under the concentration–time curve over a 24-h period (AUC0–24) were significantly associated with hypofibrinogenaemia (P < 0.05). Furthermore, it was found that AUC0–24 is the optimal predictor of TGC-induced hypofibrinogenaemia. The optimal cut-off for the AUC0–24 of TGC in ICU patients was determined to be 17.03 mg h/L. TGC exposure is highly predictive of TGC-induced hypofibrinogenaemia. We recommend closely monitoring plasma concentrations of TGC in patients to ensure patient efficacy and safety.
- 25 September 2024
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 38 (12) , 1063-1070
Optimizing the individual dosing of paroxetine in major depressive disorder with therapeutic drug monitoring
Introduction: Previous studies have examined the correlation between paroxetine concentrations and therapeutic efficacy in patients diagnosed with major depressive disorder (MDD), but findings have been contradictory. Aims: This study aimed to investigate the relationships among plasma concentrations, severity of symptoms, and adverse drug reactions (ADRs) to optimize individual dosing. Methods: Eighty-seven MDD patients, after completing treatment with paroxetine, were divided into low-concentration (LC, n = 38), medium-concentration (MC, n = 27), and high-concentration (HC, n = 22) groups, based on cutoff value concentrations with the 50% response rate and the laboratory alert level from the 2017 consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. The severity of depression and anxiety was evaluated using a 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA), respectively. Dosage, plasma concentrations, scale scores, and ADRs were recorded across the three groups at different treatment stages to define the therapeutic reference range. Results: The 4-week plasma concentration of paroxetine (65.00 ng/mL) could predict the clinical response in MDD patients at 8 weeks. Symptom relief in patients with 4-week paroxetine concentrations ranging from 65.00 to 120.00 ng/mL at 8 weeks was greater than in those with concentrations below 65.00 ng/mL, with no significant difference observed above this range. In addition, more cases of liver injury and weight gain were observed in patients with high paroxetine concentrations. Conclusion: Our results support that early paroxetine concentration may predict clinical efficacy and the incidence of ADRs, thus improving individual dosing regimens for MDD patients.
- 25 September 2024
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 38 (12) , 1063-1070
Optimizing the individual dosing of paroxetine in major depressive disorder with therapeutic drug monitoring
Introduction: Previous studies have examined the correlation between paroxetine concentrations and therapeutic efficacy in patients diagnosed with major depressive disorder (MDD), but findings have been contradictory. Aims: This study aimed to investigate the relationships among plasma concentrations, severity of symptoms, and adverse drug reactions (ADRs) to optimize individual dosing. Methods: Eighty-seven MDD patients, after completing treatment with paroxetine, were divided into low-concentration (LC, n = 38), medium-concentration (MC, n = 27), and high-concentration (HC, n = 22) groups, based on cutoff value concentrations with the 50% response rate and the laboratory alert level from the 2017 consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. The severity of depression and anxiety was evaluated using a 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA), respectively. Dosage, plasma concentrations, scale scores, and ADRs were recorded across the three groups at different treatment stages to define the therapeutic reference range. Results: The 4-week plasma concentration of paroxetine (65.00 ng/mL) could predict the clinical response in MDD patients at 8 weeks. Symptom relief in patients with 4-week paroxetine concentrations ranging from 65.00 to 120.00 ng/mL at 8 weeks was greater than in those with concentrations below 65.00 ng/mL, with no significant difference observed above this range. In addition, more cases of liver injury and weight gain were observed in patients with high paroxetine concentrations. Conclusion: Our results support that early paroxetine concentration may predict clinical efficacy and the incidence of ADRs, thus improving individual dosing regimens for MDD patients.
- 1 August 2024
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 27 (12) , 1808-1822
Network Pharmacology and Experimental Validation Explore the Pharmacological Mechanisms of Herb Pair for Treating Rheumatoid Arthritis
Objective: This study aimed to elucidate the multitarget mechanism of the Mori Ramulus - Taxilli Herba (MT) herb pair in treating rheumatoid arthritis (RA). Methods: The targets of the herb pair and RA were predicted from databases and screened through cross-analysis. The core targets were obtained using protein-protein interaction (PPI) network analysis. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed. Finally, animal experiments were conducted to validate the anti-RA effect and mechanism of this herb pair. Results: This approach successfully identified 9 active compounds of MT that interacted with 6 core targets (AKT1, TNF, IL6, TP53, VEGFA, and IL1β). Pathway and functional enrichment analyses revealed that MT had significant effects on the TNF and IL-17 signaling pathways. The consistency of interactions between active components and targets in these pathways was confirmed through molecular docking. Moreover, the potential therapeutic effect of MT was verified in vivo, demonstrating its ability to effectively relieve inflammation by regulating these targeted genes and pathways. Conclusion: The present work suggests that the therapeutic effect of MT herb pair on RA may be attributed to its ability to regulate the TNF signaling pathway and IL-17 signaling pathway.
- 1 August 2024
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 27 (12) , 1808-1822
Network Pharmacology and Experimental Validation Explore the Pharmacological Mechanisms of Herb Pair for Treating Rheumatoid Arthritis
Objective: This study aimed to elucidate the multitarget mechanism of the Mori Ramulus - Taxilli Herba (MT) herb pair in treating rheumatoid arthritis (RA). Methods: The targets of the herb pair and RA were predicted from databases and screened through cross-analysis. The core targets were obtained using protein-protein interaction (PPI) network analysis. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed. Finally, animal experiments were conducted to validate the anti-RA effect and mechanism of this herb pair. Results: This approach successfully identified 9 active compounds of MT that interacted with 6 core targets (AKT1, TNF, IL6, TP53, VEGFA, and IL1β). Pathway and functional enrichment analyses revealed that MT had significant effects on the TNF and IL-17 signaling pathways. The consistency of interactions between active components and targets in these pathways was confirmed through molecular docking. Moreover, the potential therapeutic effect of MT was verified in vivo, demonstrating its ability to effectively relieve inflammation by regulating these targeted genes and pathways. Conclusion: The present work suggests that the therapeutic effect of MT herb pair on RA may be attributed to its ability to regulate the TNF signaling pathway and IL-17 signaling pathway.
- 21 September 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (11) , 103453
Roles of interferon induced protein with tetratricopeptide repeats (IFIT) family in autoimmune disease
- 21 September 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (11) , 103453
Roles of interferon induced protein with tetratricopeptide repeats (IFIT) family in autoimmune disease
- 6 July 2023
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 92 (3) , 165-179
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
As a new means of oncology treatment, immune checkpoint inhibitors (ICIs) can improve survival rates in patients with resistant or refractory tumors. However, there are obvious inter-individual differences in the unsatisfactory response rate, drug resistance rate and the occurrence of immune-related adverse events (irAE). These questions have sparked interest in researchers looking for a way to screen sensitive populations and predict efficacy and safety. Therapeutic drug monitoring (TDM) is a way to ensure the safety and effectiveness of medication by measuring the concentration of drugs in body fluids and adjusting the medication regimen. It has the potential to be an adjunctive means of predicting the safety and efficacy of ICIs treatment. In this review, the author outlined the pharmacokinetic (PK) characteristics of ICIs in patients. The feasibility and limitations of TDM of ICIs were discussed by summarizing the relationships between the pharmacokinetic parameters and the efficacy, toxicity and biomarkers.
- 6 July 2023
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 92 (3) , 165-179
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
As a new means of oncology treatment, immune checkpoint inhibitors (ICIs) can improve survival rates in patients with resistant or refractory tumors. However, there are obvious inter-individual differences in the unsatisfactory response rate, drug resistance rate and the occurrence of immune-related adverse events (irAE). These questions have sparked interest in researchers looking for a way to screen sensitive populations and predict efficacy and safety. Therapeutic drug monitoring (TDM) is a way to ensure the safety and effectiveness of medication by measuring the concentration of drugs in body fluids and adjusting the medication regimen. It has the potential to be an adjunctive means of predicting the safety and efficacy of ICIs treatment. In this review, the author outlined the pharmacokinetic (PK) characteristics of ICIs in patients. The feasibility and limitations of TDM of ICIs were discussed by summarizing the relationships between the pharmacokinetic parameters and the efficacy, toxicity and biomarkers.